Optimal Surgical Timing after Neoadjuvant Therapy for Stage IIIa Non-Small Cell Lung Cancer.
Patients with clinically/pathologically diagnosed stageIIIa non-small cell lung cancer(NSCLC) considered for surgery are recommended to undergo neoadjuvant chemotherapy with/without radiation. Timing of operation after therapy is not standardized. We investigate timing of intervention after neoadjuvant therapy and impact on outcomes in this demographic. The National Cancer Database was queried for patients with clinical/pathological StageIIIa NSCLC between 2010-2015. Patients were then divided into short(<77days),mid(77-114days)and long-delay(>114days)groups based on interquartile values. These groups were then compared for age, race, gender, insurance type, Charlson-Deyo Score, length of stay, readmission rate and overall survival based on timing of operation. There were 31357 patients with clinical/pathological StageIIIs NSCLC. 5946 patients underwent surgical intervention. Preoperatively, 3593 patients underwent chemo-radiotherapy, 2185 underwent chemotherapy only and 168 patients received radiation alone. The short, mid and long delay groups were clinically and statistically similar in age, gender, insurance type, comorbidity index, treating facility type and distance from home. Long delay groups had larger tumor size compared to other groups. Postoperative length of stay, rates of 30-day readmission as well as 30-and 90-day mortality were similar across all groups. Cox modeling demonstrated a significant difference in survival when patients underwent earlier operative intervention compared to late and when patients received chemoradiation compared to chemotherapy alone. Short, mid and long delay groups 1-year survival was 82%, 83% and 80% and 3-year survival was 59%, 58% and 52% respectively(p=0.0003). The delay in surgical resection of StageIIIa NSCLC is not associated increased early mortality, however it is associated with worse 3-year post-resection survival.